All the latest hires in our weekly column.
Horizon Discovery has appointed to its scientific advisory board three experts in CRISPR (clustered regularly interspaced short palindromic repeats) technology, a gene editing tool.
Emmanuelle Charpentier (pictured), Keith Joung and Feng Zhang will join the life sciences tools company as gene editing advisors.
Charpentier is the current head of the Department of Regulation in Infection Biology at the Helmholtz Centre for Infection Research in Braunschweig and Hannover Medical School. She is known for her work on bacterial immunity and uncovering key functional components of the bacterial CRISPR-Cas9 system.
Joung is Associate Chief of Pathology for Research at Massachusetts General Hospital and is an Associate Professor of Pathology at Harvard Medical School. He has worked on methods for targeted genome editing using engineered zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR-Cas9.
Zhang is currently serving as W.M. Keck Career Development Professor at the Massachusetts Institute of Technology (MIT). He engineered the CRISPR-Cas9 system for genome editing in mammalian cells, as published in Science in 2013.
Copyright - Unless otherwise stated all contents of this web site are © 2017 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Manufacturers are investing in capacity and technology to help close the “market gap” for services while expanding...
Outsourcing-Pharma presents this month's roundup of who is moving where in the contract research and manufacturing industry.
Outsourcing-Pharma presents this month's round up of who is moving where in the contract research and manufacturing...
From a new administration under president-elect Donald Trump, to continued consolidation, the CRO and CMO industry can...
As 2016 comes to a close, Outsourcing-Pharma.com looks back at some of the major mergers and acquisitions...